Granisetron Hydrochloride for Injection

Pharmacological action: This product is a highly selective 5-HT3 receptor antagonist, which has a good preventive and therapeutic effect on nausea and vomiting caused by radiotherapy, chemotherapy and surgery. Factors such as radiotherapy, chemotherapy and surgical operations can cause enterochromaffin cells to release 5-HT, and 5-HT can activate the 5-HT3 receptors of the central nervous system or vagus nerve to cause vomiting reflex. The mechanism of this product in controlling nausea and vomiting is to antagonize the 5-HT3 receptors in the central chemoreceptor area and peripheral vagus nerve endings, thereby inhibiting the occurrence of nausea and vomiting. This product has high selectivity and no side effects such as extrapyramidal reactions and excessive sedation. Toxicological studies: Genetic toxicity: This product was tested in the Ames test, mouse lymphoma cell forward mutation test, mouse micronucleus test and in vivo and in vitro rat hepatocytes.

Granisetron Hydrochloride

This product is white or off-white loose mass or powder.

Used for nausea and vomiting caused by radiotherapy and cytotoxic chemotherapy.

Intravenous injection: The adult dosage is usually 3 mg, diluted with 20-50 ml of 5% glucose injection or 0.9% sodium chloride injection, and injected intravenously 30 minutes before chemotherapy. The administration time should exceed 5 minutes. Most patients only need to be given once, and the prevention effect on nausea and vomiting can exceed 24 hours. If necessary, the number of administrations can be increased by 1 to 2 times, but the maximum daily dose should not exceed 9 mg. Patients with liver and kidney dysfunction do not need to adjust the dosage.

Common adverse reactions include headache, fatigue, fever, constipation, and occasional transient asymptomatic increase in liver aminotransferase. These reactions are mild and do not require special treatment.

1. Patients who are allergic to this product or related compounds are prohibited from using this product. 2. Patients with gastrointestinal obstruction are prohibited from using this product.

1Granisetron does not induce or inhibit the cytochrome P-450 drug metabolizing enzyme system. 2Because granisetron is metabolized by the hepatic cytochrome P-450 drug metabolizing enzyme, induction or inhibition of this enzyme could alter the clearance rate and half-life of granisetron.

Keep away from light and store in a sealed container below 30℃. The shelf life is tentatively 18 months.

3mg (as granisetron)

Yuanda Pharmaceutical Huangshi Feiyun Pharmaceutical Co., Ltd.

• Founded in:

  2013-02-22

• Address:

  No. 69, Jinshan Avenue East, Huangshi City

• Tax NO.:

  91420200060689700K

• Registered Funds:

  125 million yuan

• Website:

  Log in to view

• Email:

  Log in to view